Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of July 2025. The Company is a foreign private issuer based in Tel Aviv, Israel, primarily engaged in biotechnology and pharmaceutical development. The filing focuses on corporate developments regarding a proposed merger and strategic collaborations rather than routine financial reporting.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of material events and does not contain a financial statement or quarterly results summary.
Material Changes and Corporate Developments
- Merger with AutoMax Motors Ltd.: The SEC has declared the Form F-4 Registration Statement effective regarding the proposed merger between SciSparc and AutoMax Motors Ltd. The Company urges investors to review the proxy statement/prospectus before making voting decisions.
- Extension of LOI with Miza III Ventures Inc.: On July 31, 2025, SciSparc entered into a third amendment to its non-binding letter of intent (LOI) with Miza III Ventures Inc. The deadline to enter into definitive agreements was extended from June 30, 2025, to October 15, 2025. The closing deadline was extended from July 31, 2025, to October 31, 2025.
- Patent Filing: The Company announced a collaboration with Clearmind resulting in the filing of an international patent application for a novel combination therapy targeting weight loss and fatty liver disease.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the timing of the proposed transactions with AutoMax and Miza III Ventures. Management notes that these statements are subject to risks and uncertainties, and actual results may differ materially. The Company disclaims any obligation to update these statements. Specific risk factors are referenced in the Company's Annual Report on Form 20-F filed on April 24, 2025.
Investor Verification Checklist
- Verify the terms of the proposed merger with AutoMax Motors Ltd. by reviewing the effective Form F-4 Registration Statement and proxy statement/prospectus.
- Confirm the current status of the LOI with Miza III Ventures Inc. and the new definitive agreement deadline of October 15, 2025.
- Review the details of the international patent application filed with Clearmind regarding weight loss and fatty liver disease therapies.
- Check the Company's Form 20-F (filed April 24, 2025) for the most recent audited financial data, as this 6-K does not contain financial metrics.